Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.58B |
| 2 |
Amphenol
APH
|
+$1.06B |
| 3 |
Eli Lilly
LLY
|
+$896M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$780M |
| 5 |
Snowflake
SNOW
|
+$615M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$2.24B |
| 2 |
NVIDIA
NVDA
|
+$1.89B |
| 3 |
Mercado Libre
MELI
|
+$1.5B |
| 4 |
Netflix
NFLX
|
+$1.32B |
| 5 |
Nike
NKE
|
+$826M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.63% |
| 2 | Communication Services | 15.64% |
| 3 | Consumer Discretionary | 12.05% |
| 4 | Healthcare | 9.65% |
| 5 | Financials | 6.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Renasant Corp
RNST
$3.91B
| $45M | 0.03% |
1,276,458
-355,587
| -22% | -$12.6M |
|
227
Natera
NTRA
$46.4B
| $44.9M | 0.03% |
195,943
-144,366
| -42% | -$30.1M |
|
228
Tandem Diabetes Care
TNDM
$1.56B
| $44.4M | 0.03% |
2,021,376
+601,260
| +42% | +$10.9M |
|
229
TTM Technologies
TTMI
$14.5B
| $44.2M | 0.03% |
640,047
+610,363
| +2,056% | +$39.8M |
|
230
iShares Russell 1000 Growth ETF
IWF
$128B
| $44M | 0.03% |
372,000
+263,016
| +241% | +$31.2M |
|
231
Chefs' Warehouse
CHEF
$4.5B
| $43.8M | 0.03% |
702,128
-34,888
| -5% | -$2.1M |
|
232
Apogee Therapeutics
APGE
$10.2B
| $43.7M | 0.03% |
+578,627
| New | +$36.4M |
|
233
Adaptive Biotechnologies
ADPT
$3.97B
| $43.4M | 0.03% |
2,674,668
+1,363,181
| +104% | +$22.2M |
|
234
Amgen
AMGN
$222B
| $43.4M | 0.03% |
132,464
-91,343
| -41% | -$29M |
|
235
CBRE Group
CBRE
$42.9B
| $43.2M | 0.03% |
268,456
-7,322
| -3% | -$1.15M |
|
236
Helios Technologies
HLIO
$2.76B
| $42.6M | 0.03% |
+796,101
| New | +$42.9M |
|
|
MRSH
237
Marsh
MRSH
$91.5B
| $42.5M | 0.03% |
229,075
-370,938
| -62% | -$69.3M |
|
238
Disc Medicine
IRON
$2.97B
| $42.3M | 0.03% |
+532,079
| New | +$45M |
|
239
Impinj
PI
$5.6B
| $42.2M | 0.03% |
242,504
-5,041
| -2% | -$898K |
|
240
Regal Rexnord
RRX
$11.9B
| $41.5M | 0.02% |
295,785
-83,160
| -22% | -$11.8M |
|
241
Procore
PCOR
$8.67B
| $41.4M | 0.02% |
569,097
+46,355
| +9% | +$3.43M |
|
242
Cameco
CCJ
$42.4B
| $41.1M | 0.02% |
449,577
-68,067
| -13% | -$6.13M |
|
|
PVLA
243
Palvella Therapeutics
PVLA
$2.27B
| $40.6M | 0.02% |
387,483
+280,573
| +262% | +$23.9M |
|
244
Blackstone
BX
$110B
| $40.3M | 0.02% |
261,761
+62
| +0% | +$9.42K |
|
245
Core & Main
CNM
$8.71B
| $40.3M | 0.02% |
775,592
-1,311,574
| -63% | -$67.3M |
|
246
LPL Financial
LPLA
$28.6B
| $39.9M | 0.02% |
111,667
-993,283
| -90% | -$351M |
|
247
GeneDx Holdings
WGS
$2.3B
| $39.3M | 0.02% |
302,149
-296,277
| -50% | -$40.7M |
|
248
Kymera Therapeutics
KYMR
$8.94B
| $38.6M | 0.02% |
496,665
-531,074
| -52% | -$35.9M |
|
249
Kanzhun
BZ
$7.36B
| $38.5M | 0.02% |
1,891,265
-785,390
| -29% | -$17M |
|
250
Republic Services
RSG
$65.7B
| $38.5M | 0.02% |
181,751
-17,109
| -9% | -$3.68M |
|
Similar funds
Jennison Associates's Q4 2025 Portfolio in Review
As of Q4 2025, Jennison Associates held 652 positions worth $167B, down 3% from $172B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Jennison Associates withdrew a net $7.12B in Q4 2025, closing 78 positions and reducing 263 holdings. Its most notable exit was Nike, an estimated $826M position sold in full.
By sector, the portfolio is most concentrated in Technology at 42% of assets, up from 41% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, Jennison Associates opened a new position in Merck worth $585M.
- Jennison Associates's largest Q4 2025 buy was Merck: 5,559,488 shares worth $585M.
- Jennison Associates added most to Advanced Micro Devices in Q4 2025, an estimated $1.58B increase.
- Jennison Associates's biggest Q4 2025 reduction was Meta Platforms (Facebook), cutting an estimated $2.24B.
- Jennison Associates fully exited Nike in Q4 2025, selling an estimated $826M.
- Jennison Associates's ten largest holdings make up 48% of its $167B portfolio in Q4 2025.
- Jennison Associates opened 92 new positions and closed 78 in Q4 2025.
- Jennison Associates's portfolio value fell 3% quarter-over-quarter to $167B.
Based on Jennison Associates's 13F filing for Q4 2025, filed 30 Jan 2026.